Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study-Reference-Cited by-同舟云学术

Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study

Published:2023-11-11 Issue:1 Volume:41 Page:315-330
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Schmalzing Marc^ORCID,Kellner Herbert,Askari Ayman,De Toro Santos Javier,Vazquez Perez-Coleman Julio Cesar,Foti Rosario,Jeka Sławomir,Haraoui Boulos,Allanore Yannick,Peichl Peter,Oehri Martin,Rahman Masiur,Furlan Fabricio,Romero Elisa,Hachaichi Sohaib,Both Charlotte,Brueckmann Ines,Sheeran Tom

Funder

This study was funded by Hexal AG, a Sandoz company.

Universitätsklinikum Würzburg

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02706-8.pdf

Reference26 articles.

1. Mease PJ, Liu M, Rebello S, et al. Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corrona registries. Rheumatol Ther. 2019;6(4):529–42.

2. Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis: a systematic literature review. Rheumatol Ther. 2022;9(2):331–78.

3. Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022;64:102234.

4. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002;4(5):307–21.

5. Kerola AM, Rollefstad S, Kazemi A, et al. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol. 2023;51(1):42–50.